Major Milestone Achieved: SiPore® Data Strengthens Path to World's First Oral Medical Device for Blood Sugar Control in Prediabetics
· Sigrid Therapeutics announces publication of key scientific study showing activity and stability of amylase remain unaffected when confined in SiPore® mesoporous silica pores · Results provide further support for medical device claim that MSPs act exclusively as “molecular sieves” · Sigrid’s patented MSPs technology SiPore® to physically prevent digestive enzymes from interacting with food already being used in prediabetes, diabetes, weight control and oral health applications Stockholm, August 16[th], 2023: Sigrid Therapeutics today announced the publication of a scientific study